File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Serum apolipoprotein(a) correlates with growth hormone levels in Chinese patients with acromegaly

TitleSerum apolipoprotein(a) correlates with growth hormone levels in Chinese patients with acromegaly
Authors
Keywordsacromegaly
apolipoprotein(a)
growth hormone
lipoproteins
octreotide
Issue Date1993
PublisherElsevier Ireland Ltd. The Journal's web site is located at http://www.elsevier.com/locate/atherosclerosis
Citation
Atherosclerosis, 1993, v. 104 n. 1-2, p. 183-188 How to Cite?
AbstractUntreated acromegaly is associated with an increased cardiovascular morbidity and mortality. The contribution of altered lipid metabolism remains unclear. We investigated the relationship between serum apolipoprotein(a) (apo(a)) and growth hormone (GH) levels in 15 patients with acromegaly before and during treatment with octreotide, a long-acting somatostatin analogue, 288-600 μg/day s.c., for 6 months. Before treatment serum apo(a) was significantly elevated in acromegalic patients (geometric mean being 323 U/l vs. 142 U/l in controls (n = 92; P < 0.01)). Octreotide treatment resulted in significant reductions in serum apo(a) concentration (F = 7.22; P < 0.01; geometric mean being 232 U/l and 248 U/l at 3 months and 6 months respectively) and apo(a) concentrations on treatment were not significantly different from control values. There were significant reductions in serum GH (F = 7.30; P < 0.01), insulin growth factor 1 (IGF1) (F = 31.4, P < 0.001) and insulin (F = 4.57; P < 0.05) concentrations. Plasma glycosylated haemoglobin levels were unchanged. Apo(a) levels correlated with serum GH (r = 0.450; P < 0.01) but showed no correlation with basal insulin concentrations. Serum HDL cholesterol increased on treatment (F = 4.29; P < 0.05). Triglycerides were reduced only in the 12 patients without diabetes mellitus (P = 4.75; P < 0.05). No significant change in LDL cholesterol occurred. Our findings suggest that apo(a) may constitute another cardiovascular risk factor in untreated acromegaly and that GH may be involved in the regulation of circulating apo(a) concentration.
Persistent Identifierhttp://hdl.handle.net/10722/162018
ISSN
2015 Impact Factor: 3.942
2015 SCImago Journal Rankings: 1.819
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLam, KSLen_HK
dc.contributor.authorPang, RWCen_HK
dc.contributor.authorJanus, EDen_HK
dc.contributor.authorKung, AWCen_HK
dc.contributor.authorWang, CCLen_HK
dc.date.accessioned2012-09-05T05:16:42Z-
dc.date.available2012-09-05T05:16:42Z-
dc.date.issued1993en_HK
dc.identifier.citationAtherosclerosis, 1993, v. 104 n. 1-2, p. 183-188en_HK
dc.identifier.issn0021-9150en_HK
dc.identifier.urihttp://hdl.handle.net/10722/162018-
dc.description.abstractUntreated acromegaly is associated with an increased cardiovascular morbidity and mortality. The contribution of altered lipid metabolism remains unclear. We investigated the relationship between serum apolipoprotein(a) (apo(a)) and growth hormone (GH) levels in 15 patients with acromegaly before and during treatment with octreotide, a long-acting somatostatin analogue, 288-600 μg/day s.c., for 6 months. Before treatment serum apo(a) was significantly elevated in acromegalic patients (geometric mean being 323 U/l vs. 142 U/l in controls (n = 92; P < 0.01)). Octreotide treatment resulted in significant reductions in serum apo(a) concentration (F = 7.22; P < 0.01; geometric mean being 232 U/l and 248 U/l at 3 months and 6 months respectively) and apo(a) concentrations on treatment were not significantly different from control values. There were significant reductions in serum GH (F = 7.30; P < 0.01), insulin growth factor 1 (IGF1) (F = 31.4, P < 0.001) and insulin (F = 4.57; P < 0.05) concentrations. Plasma glycosylated haemoglobin levels were unchanged. Apo(a) levels correlated with serum GH (r = 0.450; P < 0.01) but showed no correlation with basal insulin concentrations. Serum HDL cholesterol increased on treatment (F = 4.29; P < 0.05). Triglycerides were reduced only in the 12 patients without diabetes mellitus (P = 4.75; P < 0.05). No significant change in LDL cholesterol occurred. Our findings suggest that apo(a) may constitute another cardiovascular risk factor in untreated acromegaly and that GH may be involved in the regulation of circulating apo(a) concentration.en_HK
dc.languageengen_US
dc.publisherElsevier Ireland Ltd. The Journal's web site is located at http://www.elsevier.com/locate/atherosclerosisen_HK
dc.relation.ispartofAtherosclerosisen_HK
dc.subjectacromegalyen_HK
dc.subjectapolipoprotein(a)en_HK
dc.subjectgrowth hormoneen_HK
dc.subjectlipoproteinsen_HK
dc.subjectoctreotideen_HK
dc.subject.meshAcromegaly - Blood - Drug Therapyen_US
dc.subject.meshAdulten_US
dc.subject.meshApolipoproteins A - Analysisen_US
dc.subject.meshCholesterol, Hdl - Blooden_US
dc.subject.meshCholesterol, Ldl - Blooden_US
dc.subject.meshFemaleen_US
dc.subject.meshGrowth Hormone - Blooden_US
dc.subject.meshHemoglobin A, Glycosylated - Analysisen_US
dc.subject.meshHumansen_US
dc.subject.meshInsulin - Blooden_US
dc.subject.meshInsulin-Like Growth Factor I - Analysisen_US
dc.subject.meshMaleen_US
dc.subject.meshOctreotide - Therapeutic Useen_US
dc.subject.meshProspective Studiesen_US
dc.subject.meshTriglycerides - Blooden_US
dc.titleSerum apolipoprotein(a) correlates with growth hormone levels in Chinese patients with acromegalyen_HK
dc.typeArticleen_HK
dc.identifier.emailLam, KSL: ksllam@hku.hken_HK
dc.identifier.emailPang, RWC: robertap@hkucc.hku.hken_HK
dc.identifier.emailKung, AWC: awckung@hku.hken_HK
dc.identifier.authorityLam, KSL=rp00343en_HK
dc.identifier.authorityPang, RWC=rp00274en_HK
dc.identifier.authorityKung, AWC=rp00368en_HK
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1016/0021-9150(93)90189-2-
dc.identifier.pmid8141841-
dc.identifier.scopuseid_2-s2.0-0027741436en_HK
dc.identifier.volume104en_HK
dc.identifier.issue1-2en_HK
dc.identifier.spage183en_HK
dc.identifier.epage188en_HK
dc.identifier.isiWOS:A1993MR22600019-
dc.publisher.placeIrelanden_HK
dc.identifier.scopusauthoridLam, KSL=8082870600en_HK
dc.identifier.scopusauthoridPang, RWC=7004376659en_HK
dc.identifier.scopusauthoridJanus, ED=7006936536en_HK
dc.identifier.scopusauthoridKung, AWC=7102322339en_HK
dc.identifier.scopusauthoridWang, CCL=7501631357en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats